Form 4: ACADIA PHARMACEUTICALS Director James Daly Reports Equity Grants and RSU Conversion

ACADIA PHARMACEUTICALS Director James M. Daly reported the conversion of restricted stock units into common stock and the grant of new stock options and restricted stock units as part of his compensation.

Summary

• James M. Daly, a Director of ACADIA PHARMACEUTICALS INC (ACAD), reported transactions on May 29, 2025.
• Mr. Daly acquired 9,387 shares of common stock through the conversion of previously held restricted stock units (RSUs).
• These 9,387 restricted stock units vested in full on May 29, 2025, coinciding with the company's annual meeting of stockholders.
• Following this transaction, Mr. Daly beneficially owns 34,041 shares of common stock.
• Additionally, Mr. Daly was granted 13,793 Director Stock Options with an exercise price of $22.29 per share, expiring on May 28, 2035.
• These stock options will vest quarterly over one year, with the final tranche vesting on the earlier of one year from the grant date or the next annual meeting of stockholders.
• Mr. Daly also received a grant of 8,107 new Restricted Stock Units (RSUs).
• These new RSUs will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a routine compensation event, it signifies continued alignment of a director's interests with the company's performance through equity ownership. There are no negative implications from this specific filing.

Positives

• The acquisition of common stock and the grant of new equity awards to Director James M. Daly align his interests with those of shareholders, promoting long-term value creation.
• The vesting of previously granted restricted stock units indicates the fulfillment of prior compensation agreements.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, specifically related to director compensation. It reflects the common practice in the pharmaceutical industry, and publicly traded companies in general, of compensating directors and executives with equity awards to align their incentives with shareholder interests and encourage long-term commitment.

Related Party Transactions

• The reported transactions are related party transactions as they involve equity compensation granted by ACADIA PHARMACEUTICALS INC to its Director, James M. Daly.

Stakeholder Impact

• Shareholders: The grant of new equity awards may result in minor dilution over time as shares are issued upon vesting and exercise, but it also serves to align the director's financial interests with shareholder value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 13,793 Director Stock Options will vest quarterly over one year, with the final tranche vesting on the earlier of one year following the grant date or the next annual meeting of stockholders.
• The 8,107 new Restricted Stock Units will vest in full on the earlier of one year following the grant date or the next annual meeting of stockholders.

Key Dates

Keywords

ACADIA PHARMACEUTICALS, ACAD, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, SEC Filing